Du, W., Zhan, J., Wu, K., Wang, Y., Zhang, L., & Hong, S. (2025). Early kinetics of serum amyloid A predict clinical benefit to first-line chemoimmunotherapy and immunotherapy in advanced non-small cell lung cancer. Biomarker Research, 13(1), 1. https://doi.org/10.1186/s40364-025-00791-1
Chicago-referens (17:e uppl.)Du, Wei, Jianhua Zhan, Kai Wu, Yanming Wang, Li Zhang, och Shaodong Hong. "Early Kinetics of Serum Amyloid A Predict Clinical Benefit to First-line Chemoimmunotherapy and Immunotherapy in Advanced Non-small Cell Lung Cancer." Biomarker Research 13, no. 1 (2025): 1. https://doi.org/10.1186/s40364-025-00791-1.
MLA-referens (9:e uppl.)Du, Wei, et al. "Early Kinetics of Serum Amyloid A Predict Clinical Benefit to First-line Chemoimmunotherapy and Immunotherapy in Advanced Non-small Cell Lung Cancer." Biomarker Research, vol. 13, no. 1, 2025, p. 1, https://doi.org/10.1186/s40364-025-00791-1.
